Xilio Therapeutics raises $35.8mln, achieves AbbVie milestone, and extends cash runway.

Xilio Therapeutics has received $35.8mln in gross proceeds from Series B warrant exercises, extending its cash runway into Q2 2027. The company has achieved a development milestone for its masked antibody-based program under an AbbVie agreement and nominated a development candidate for its wholly-owned masked T cell engager program targeting CLDN18.2. Xilio has also appointed Sara Bonstein as chair of its board of directors.